Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neur...( Pre-Clinical Study Results for Mem...)

Pre-Clinical Study Results for Memory and Cognition Validate Clinical

Development Program

LONDON, September 24 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) ("Amarin" or "Company") announced that the results of a pre-clinical program in memory and cognition using ultra-pure eicosapentanoic acid (EPA) have been published in the "Journal of Neurochemistry" (Minogue AM et al 2007 J. Neurochem. 10.1111/j.1471-4159.2007.04848.x) in an article entitled, "Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid."

The preclinical study was conducted by Professor Marina Lynch, Department of Physiology, Institute of Neuroscience, Trinity College, Dublin, and demonstrated that EPA attenuates the age-related and beta amyloid-induced impairment of Long Term Potentiation (LTP). LTP is a phenomenon considered an important marker of the integrity of neural processes involved in memory and cognition. This mechanism was identified by Professor Eric Kandel as fundamental in mediating memory and cognition and, consequently, LTP is considered a major mechanism by which the brain learns and maintains memories.

The study confirmed that EPA reduced concentrations of the pro-inflammatory interleukin 1beta (IL-beta), and phosphorylation of the stress-activated protein kinase, c-jun N-terminal kinase (JNK). These factors are associated with inhibition of LTP thus potentially impair memory and cognition.

Commenting on the study, Professor Lynch said, "These findings identify an important potential role for EPA in modulating beta-amyloid-induced and age-related changes in the brain and the present findings suggest that the bene
'/>"/>